Cervical Squamous Cell Carcinoma — Variants & evidence

Cervical Squamous Cell Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

2 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Amplification1
(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID471 In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival. PMID 21730982 · Iida et al., 2011 · Open in CIViC	civic
TACC3 Fusion1
Fexagratinib	Predictive	C	Supports Sensitivity Response	1	submitted	EID9241 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic

Data updated 2 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.